Skip to content
Syntekabio Inc. logo — AI Platform for Drug Discovery & Precision Medicine  
(22633...

Syntekabio Inc.

AI Platform for Drug Discovery & Precision Medicine (226330:KOSDAQ)

Founded 2009 United States New York, United States 36 employees Series C Total: $31.72B Biotechnology, Health Care +1

General Information

Company Name Syntekabio Inc.
Founded Year 2009
Location United States New York, United States
Employees 36
Industries Biotechnology, Health Care, Information Technology
Funding Stage Series C
Business Model B2B, SaaS, Platform
Revenue Model Licensing, Subscription, Service Fee
Offices as of Nov 2026
New York, United States Daejeon, Korea South Seoul, Korea South
Social

BounceWatch is an independent company data service, not affiliated with Syntekabio Inc.. To contact Syntekabio Inc., visit syntekabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Syntekabio Inc. compare?

A PDF of Syntekabio Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Syntekabio Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Syntekabio Inc.

Syntekabio Inc., headquartered in the United States with a significant presence in South Korea, stands at the vanguard of biotechnological innovation. Founded in 2009, the company is revolutionizing the fields of Biotechnology, Health Care, and Information Technology through its pioneering use of Artificial Intelligence and Next Generation Sequencing.

The company leverages a proprietary supercomputing infrastructure and robust genomic database to enhance the precision and efficacy of drug discovery and development. This technological synergy aids in identifying promising molecular entities, paving the way for novel therapeutic solutions.

With its last known investment being a $17.20M Series C financing round on 01 July 2019, Syntekabio seeks strategic partnerships with academic, industrial, and governmental institutions to drive global advancements in healthcare.

Business keywords: AI Drug Discovery, Precision Medicine, Next Generation Sequencing, Genomic Database, Supercomputing Infrastructure, Personalized Medicine, Bioinformatics, Decrypted Whole Genome Data, Cancer Therapy, Immuno-oncology, Small Molecules, Proteins, Peptides, Gene Decoding, Vaccine Development

Services & Products

AI-driven drug discovery platforms
Supercomputing power for bioinformatics
Data center design and management
Language model-based virtual screening

Target Customers

Biotechnology Companies Pharmaceutical Manufacturers Biomedical Researchers Academic Institutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $17.20M -
01 Jul 2019
Series C KRW19.70B 2
Timewise Investment, Yuhan Corporation
01 Jan 2019
Series B KRW12.00B 3
Altos Ventures, Korea Development Bank +1
01 May 2018
Seed $880.00K 1
Altos Ventures
01 Jul 2016

Syntekabio Inc. Alternatives & Competitors

View All Alternatives
Syntekabio Inc. vs

On a quest to leverage the power of single cell genomics to discover novel drug targets and precisio...

Acquired
2 employees
Biotechnology, Health Care
Syntekabio Inc. vs
Strata Oncology
Strata Oncology United States

Strata Oncology is a high-growth, state-of-the art, precision oncology company, delivering a new sta...

Series C
31 employees
Biotechnology, Health Care
Syntekabio Inc. vs

Unifying AI and Biotech to accelerate the discovery of new medicines

157 employees
AI, Biotechnology

FAQ About Syntekabio Inc.

AI Platform for Drug Discovery & Precision Medicine (226330:KOSDAQ)
Syntekabio Inc. was founded in 2009.
Syntekabio Inc. is headquartered in New York, United States. As of Nov 2026, it also has offices in Daejeon, Korea South and Seoul, Korea South.
Syntekabio Inc. operates in Biotechnology, Health Care and Information Technology. Its work centres on AI Drug Discovery, Precision Medicine, Next Generation Sequencing and Genomic Database. Its customers include Biotechnology Companies, Pharmaceutical Manufacturers and Biomedical Researchers.
Syntekabio Inc. has a B2B, SaaS and Platform business model. Its revenue comes from Licensing, Subscription and Service Fee.
Syntekabio Inc. has approximately 36 employees.
Syntekabio Inc. has completed 4 funding rounds, raising a total of $31.72B. The latest funding stage is Series C.
Syntekabio Inc. offers: AI-driven drug discovery platforms, Supercomputing power for bioinformatics, Data center design and management, Language model-based virtual screening.
Top alternatives and competitors to Syntekabio Inc. include Celsius Therapeutics, Strata Oncology, Genesis Molecular AI, Congenica, xilis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Syntekabio Inc. and Celsius Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Syntekabio Inc., https://bouncewatch.com/company/syntekabio, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout